Monoclonal Antibodies
-
-
Supercomputing redesign of a COVID monoclonal antibody
One of the monoclonal antibodies in the therapeutic Evusheld has been computationally redesigned to restore its action against Omicron variants of the virus that causes COVID-19. Read MoreMay. 14, 2024
-
COVID antibody research conducted at VUMC lands national award
A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals, and which was optimized and developed by the global pharmaceutical company AstraZeneca, has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine. Now… Read MoreAug. 25, 2022
-
Crowe receives national award for COVID antibody research
James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. The announcement was made… Read MoreApr. 1, 2022
-
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
On Wednesday, the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center (VUMC). A number of medical conditions result in immune compromise, from treatments for many cancers… Read MoreDec. 9, 2021
-
Vanderbilt Vaccine Center a step closer to broad ebolavirus protection
A combination of two broadly acting monoclonal antibodies isolated by researchers at Vanderbilt University Medical Center protected non-human primates from ebolavirus disease, which causes severe and often-fatal hemorrhagic fever in humans. Their findings, published this week in the journal Cell, bring closer to development the first clinical therapy effective… Read MoreOct. 29, 2021